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The following review summarizes one of the early random- 
ized controlled trials of the use of thrombolytic therapy for 
acute myocardial infarction. The results of this and other 
smaller trials carried out in the early 1980s redirected the 
therapy of acute myocardial infarction from a strategy of 
reducing myocardial work and arrhythmia suppression to 
one of early reperfusion of the infarcting myocardium. The 
reduction in morbidity and mortality that have resulted 
from this shift in management can be compared in impor- 
tance to the introduction and development of coronary 
~u-tery bypass surgery and coronary artery angioplasty. 
Early Thrombolysis in 
Acute Myocardial Infarction: 
Limitation of Infarct 
Size and Improved Survival 
by M. L. Simoons, P. W. Serruys, M. van den Brand, 
J. Res, F. W. Verheugt, X. H. Krauss, W. J. Remme, 
F. Bar, C. de Zwaan, A. van der Laarse, Vermeer, and 
Lubsen (1) 
ABSTRACT 
The effect of thrombolysis in acute myocardial infarction on 
infarct size, left ventricular function, clinical course and patient 
survival was studied in a randomized trial comparing throm- 
bolysis (269patients) with conventional treatment (264 control 
patients). All 533 patients were admitted to the coronary care 
unit within 4 hours after the onset of symptoms related to the 
infarction. Baseline characteristics were similar in both groups. 
Informed consent was requested only of patients allocated to 
thrombolysis; no angiography was performed in 35. The infarct- 
related artery was patent in 65 patients and occluded in 169. 
Recanalization was achieved in 133patients. The median time 
to angiographic documentation of vessel patency was 200 
minutes after the onset of symptoms. 
The clinical course in the coronary care unit was more 
favorable after thrombolysis. Infarct size, estimated from myo- 
cardial enzyme release, was 30% lower after thrombolysis. In 
patients admitted within 1 hour after the onset of symptoms the 
reduction of infarct size was 51%, in those admitted between I 
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and 2 hours it was 31% and in those admitted later than 2 
hours it was 13%. Left ventricular function measured by 
radionuclide angiography before hospital discharge was better 
after thrombolysis (ejection fraction 48 + 15%) than in control 
patients (44 + 15%). Similar improvement was observed in 
patients with a first infarct only (thrombolysis 50 +- 14%, 
control subjects 46 + 15%), in patients with anterior infarction 
50th Anniversary Historical Article 
INTRODUCTION 
In this edition of the Journal, we release the seventh in a series 
of reviews of influential articles that have been previously 
published in ACC journals, including the American Journal of 
Cardiology (from 1958 to 1982) and JACC (from 1983 to the 
presen0. The publication of these articles is only one aspect of the 
ACC's 50th anniversary commemoration, which highlights 50 
years of leadership in cardiovascular care and education. The 
articles are intended to encourage reflection on the remarkable 
progress made in cardiovascular medicine over time, as well as to 
acknowledge the amazing prescience of some early investigators in 
anticipating and, in many cases, later guiding developments in
their field. 
The working group responsible for selecting these articles and 
asking reviewers to write editorials solicited suggestions from 
the ACC's clinical committees and individual members. 
The group achieved consensus fairly easily, including whom the 
group should ask to prepare the accompanying editorials. We 
initially drew up a llst of 14 general areas to cover in this series, 
but later found that there are several major areas of modern 
cardiology, prominently molecular cardiology, in which the truly 
landmark articles have, alas, not yet been published in JACC. 
Therefore, the working group decided not to categorize by subject, 
but instead, to concentrate on the most important articles. 
The working group, a task force of the Subcommittee for the 
Commemoration f the ACC 50th Anniversary, owes a great 
deal to Ms. May A. Roustom and the efficient and tireless taff 
at Heart House for facilitating this project. We also wish to 
thank all who suggested articles and, most important, the 
authors who prepared reviews for their willingness to contribute 
their time and wisdom. 
Influential Artides in JACC Working Group 
Sharon A. Hunt, M.D., F.A.C.C. 
Rick A. Nishimura, M.D., F.A.C.C. 
H.J.C. Swan, M.D., Ph.D., M.A.C.C. 
Michael J. Wolk, M.D., F.A.C.C. 
26B Kennedy JACC Vol. 35, No. 5, Suppl B 
Thrombolytic Therapy April 2000:25B-28B 
(thrombolysis 44 +_ 16%, contT"ol subjects 35 +- 14%) and in 
those with inferior infarction (thrombolysis 52 +- Y2%, control 
subjects 49 +- 12%). Similar results were obtained by contrast 
angiogT"aphy. 
Mortality was lower after thrombolysis. After 28 days 16 
patients allocated to thrombolysis and 31 conh-ol patients had 
died. One year survival rates were 91 and 84%, respectively. 
On the other hand, nonfatal reinfarction occurred more fre- 
quently after thrombolysis (36 patients) than in conh-ol subjects 
(16 patients). Early thrombolysis by intracorona,y streptokinase 
leads to a snlaller infarct size estimated by enzyme release, 
preserves left vent~4cular fitnction at the second week and leads 
to improved 1 year smwival. 
Originally pubfished in the Journal of the ~4merican College of Cardiology, 
April 1986. 
Revievo 
Historical Background. Before 1980, the management of
patients with acute myocardial infarction (AMI) was cen- 
tered around pharmacologic therapy directed toward man- 
aging arrhythmias and attempting to limit the size of the 
evolving infarct. Although these efforts were partially effec- 
tive, the morbidity and mortality from AMI remained high. 
In the mid 1970s, a group of cardiologists and cardiac 
surgeons in private practice in Spokane, Washington, began 
a program of urgent coronary angiography on patients 
presenting to the emergency department with evolving 
myocardial infarctions to select those who might benefit 
from emergency coronary bypass surgery. From this expe- 
rience, later reported by DeWood et al. (2), they demon- 
strated that emergency angiography could be performed 
safely in this group of patients. They also observed that in 
most patients presenting with ST elevation on the electro- 
cardiogram, immediate coronary angiography identified a 
thrombotic occlusion of the infarct-related artery. Although 
urgent bypass surgery never became widely accepted as a 
primary therapy for AMI, these observations provided 
critical background information for the later development of
both thrombolytic therapy and primary angioplasty for the 
management of AM[[. 
In 1979, two European investigators reported new ap- 
proaches to the management of coronary artery disease in 
U.S. publications. Rentrop et al. reported the successful se 
of intracoronary streptokinase (ICSK) for reperfusion of 
patients with AMI, and Gruentzig et al. described the 
development of percutaneous transluminal coronary angio- 
plasty (3,4). Although angioplasty, early in its development, 
was not yet suitable for use in the setting of acute infarction, 
ICSK therapy could be performed in any catheterization 
laboratory without special equipment or training. For this 
reason, ICSK therapy was rapidly introduced into clinical 
practice by cardiologists in Europe and North America; 
academic medical centers in Detroit, Salt Lake City, Seattle, 
Auckland, New Zealand, and Simoons's group in the 
Netherlands initiated randomized controlled trials of this 
new therapy. 
The working group on thrombolytic therapy in AMI of 
the Netherlands Interuniversity Cardiology Institute began 
their randomized controlled trial in May 1981, and their 
early results were published in April 1986 (1). These 
investigators randomized 533 patients to either ICSK or 
conventional management in a coronary care unit. The 
initial protocol required patients in whom an occluded 
infarct-related artery was identified and who were in the 
active treatment arm to undergo coronary angiography 
followed by ICSK. Later in the trial, patients allocated to 
thrombolytic therapy received an initial intravenous dose of 
500 nag of streptokinase before cardiac catheterization to
reduce the time from diagnosis to initiating thrombolytic 
therapy. In addition, when angioplasty became available, 35 
patients who had an unsatisfactory esult from ICSK un- 
derwent immediate angioplasty of the infarct-related lesion. 
Thus, the Netherlands investigators tested a strategy of early 
reperfusion therapy for AMI that utilized a combination of 
immediate coronary angiography followed by ICSK, intra- 
venous treptokinase followed by coronary angiography and 
ICSK and, later in the trial, angioplasty when thrombolytic 
therapy failed. By changing the treatment protocol as new 
methods became available, these investigators attempted to 
achieve coronary artery reperfusion as early and as com- 
pletely as possible with the drugs and techniques available to 
them at that time. 
Early results of thrombolytic therapy. In the Netherlands 
trial, the cumulative distribution of infarct size as estimated 
by serial enzyme measurements averaged 30% smaller in the 
treatment patients as compared with the control subjects 
(p = 0.0001). The left ventricular ejection fraction (EF) was 
measured by radionuclide angiography 10 to 20 days after 
infarction and was 4% higher in the lytic patients as 
compared with the control subjects (p = 0.05). At 28 days 
of mean follow-up, total mortality rate was reduced by 50% 
in the treatment patients as compared with the control 
subjects (5.9% vs. 11.7%). At the time of intermediate 
follow-up, which varied from 1 to 48 months, there con- 
tinued to be a 45% reduction in mortality in the treatment 
group as compared with the control subjects. There were 35 
patients who were allocated to thrombolytic therapy who 
did not undergo angiography or receive streptokinase. As 
required by the ZeUen technique of randomization used in 
this trial, these patients were included in the data analysis as 
being in the treatment group. In this group, there was a high 
early mortality of 14.3%. In comparison, patients who had 
an open vessel at the time of initial diagnostic angiography 
or after successful reperfusion with ICSK had a remarkably 
low mortality of 4.5%. Among the 36 patients who failed to 
reperfuse with ICSK, nine (25%) died. These results dem- 
onstrated the profound beneficial effect of early coronary 
artery reperfusion on mortality in patients with A.MI. These 
results also confirmed those of the smaller 250-patient 
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Figure 1. Survival analysis of all 533 patients allocated to intra- 
coronary streptokinase or conventional therapy (control). Numbers 
denote patients at risk at the various intervals after treatment with 
streptokinase (top) or conventional therapy (below). Follow-up 
data were complete at three years. From Simoons et al. (7). 
Western Washington Randomized Trial of Intracoronary 
Streptokinase in Acute Myocardial Infarction, which re- 
ported similar reductions in mortality (3.7% vs. 11.2%, p = 
0.02) with ICSK, and identified the importance of complete 
reperfusion for the long-term outcome of patients treated 
with thrombolytic therapy (5,6). 
Long-term follow-up of thrombolytic trials. Long-term 
follow-up has been published from the Netherlands trial, 
the combined results of three Western Washington trials 
and the two early megatrials of intravenous treptokinase 
therapy ISIS-2 and GISSI-1 (7-10). The Netherlands 
Hwestigators were the first to publish their long-term 
~bllow-up. They reported a sustained benefit of thrombo- 
lytic therapy over three to seven years. The survival curve for 
the treatment and control patients is shown in Figure 1. 
After three years, the mean survival of the lyric patients was 
87% versus 79% for the control subjects, and the five-year 
survival had a similar benefit in favor of thrombolytic 
therapy (81% vs. 71%). The overall reduction in five-year 
mortality for the treatment patients was 39% compared with 
the control subjects. The shape of the survival curve dem- 
onstrates that the benefits of thrombolytic therapy occur 
during the first few months after AMI, and after that period 
of time the survival of the two groups is similar. Both the 
ISIS-2 and GISSI-1 trials demonstrated the same pattern of 
survival over 10 years of follow-up (9,10). 
Follow-up angiographic findings predict long-term out- 
come. During the first three years of follow-up in the 
Netherlands trial, reinfarction was more common in the 
lyric patients than in the control subjects. This occurred 
most often in those with initial inferior infarctions. There 
were 422 patients with a follow-up angiogram between 10 
and 40 days after admission into the trial in whom an 
angiographic ejection fraction could be determined. Among 
these patients, the five-year survival for those with an EF 
>40% was similar in the treatment and control patients, 
being 83% and 86%, respectively. For those with an EF of 
<40%, the lytic patients had improved long-term survival 
(65% vs. 57%). The severity of the residual stenosis in the 
infarct-related coronary artery on follow-up angiography 
was also an important predictor of long-term outcome. In 
patients with a residual stenosis <90%, the five-year survival 
was 94% for treatment patients and 80% for control pa- 
tients. For those with a residual stenosis >90%, lytic therapy 
did not improve five-year survival, which was 78% in both 
groups. Thus, in patients in this trial who survived to have 
a follow-up angiogram, those with good residual eft ven- 
tricular function had excellent long-term survival regardless 
of whether or not they had received thrombolytic therapy. 
When thrombolytic therapy was unsuccessful or when a 
high grade stenosis persisted after lytic therapy, the outcome 
was less favorable. As has been apparent for several years, 
left ventricular ejection fraction is an important predictor of 
long-term outcome after myocardial infarction (MI) inde- 
pendent of the form of therapy provided to the patient. This 
trial helped establish this fact and the additional importance 
of the severity of the residual stenosis in the infarct-related 
vessel after therapy for patients' long-term survival. 
CONCLUSIONS 
Early reperfusion of the infarct-related coronary artery is the 
cornerstone of the current management of AMI. The 
Netherlands trial provided one of the important steps in the 
development of this therapy. Although it is traditional for 
clinical trials to maintain a rigid protocol for the duration of 
the study, the Netherlands investigators chose to change 
their strategy of reperfusion as new forms of therapy became 
available. Because these researchers adopted an unorthodox 
approach to clinical investigation, the results of this study 
contributed to the rapid evolution of reperfusion therapy. 
The best way to accomplish reperfusion in patients with 
evolving MI continues to be debated, although there is 
strong agreement that very early reperfusion must be ac- 
complished to preserve myocardium. In addition, normal or 
nearly normal flow (Thrombolysis in Myocardial Infarction 
grade 3) must be established in the infarct-related vessel to 
provide optimal reduction in morbidity and mortality 
(11,12). The early and long-term results of primary PTCA 
have been demonstrated to be excellent when carried out in 
an experienced laboratory by expert interventionists (13). 
Intravenous thrombolytic therapy, when applied in the first 
1 to 2 h after the onset of AMI, also yields good results, but 
despite the development of many new thrombolytic agents, 
there remains a relatively high incidence of intracranial 
hemorrhage. It now appears that a combination of platelet 
glycoprotein IlbfllIa inhibitors and a lower dose of throm- 
bolytic agents may be superior to any of the pharmacologic 
revascularizafion strategies currently in use (14). There is 
now at least a reasonable hope that in the near future 
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pharmacologic therapy that is the equal o f  pr imary angio- 
plasty wil l  be available in every communi ty  hospital in the 
U.S. I f  this occurs, we can anticipate a further important  
reduction in the morbidi ty and mortal i ty that result from 
MI .  
Reprint requests and correspondence: Dr. Kennedy, Cardiology 
II IC, 1660 South Columbian Way, Box 358280-IIIC, Seattle, 
Washington 98108-1597. 
REFERENCES 
1. Simoons ML, Serruys PW, van den Brand M, et al. Early thrombol- 
ysis in acute myocardial infarction: limitation of infarct size and 
improved survival. J Am Coil Cardiol 1986;7:717-28. 
2. DeWood MA, Spores J, Notake R, et al. Prevalence of total coronary 
occlusion during the early hours of transmural myocardial infarction. 
N Engl J Med 1980;303:897-902. 
3. Rentrop KP, Blanke H, Karsch KR, et al. Acute myocardial infarction: 
intracoronary application of nitroglycerin and streptokinase in combi- 
nation with transluminal recanalization. Clin Cardiol 1979;2:354-63. 
4. Gruentzig AR, Senning A, Siegenthaler WE. Non-operative dilata- 
tion of coronary artery stenosis: percutaneous transluminal corona.,'), 
angioplast'y. N Engl J Med 1979;301:61-8. 
5. Kennedy JW, Ritchie JL, Davis KB, Fritz JK. Western Washington 
Randomized Trial of Intracoronary Streptokinase inAcute Myocardial 
Infarction. N Engl J Med 1983;309:1477-82. 
6. Kennedy JW, Ritchie JL, Davis KB, Stadius ML, Maynard C, Fritz 
JK. The Western Washington Randomized Trial of Intracoronary 
Streptokinase in Acute Myocardial Infarction. A 12 month follow-up 
report. N Engl J Med 1985;312:1073-8. 
7. Simoons ML, Vos J, Tijssen JGP. Long term benefit of earl)' 
thrombolytic therapy in patients with acute myocardial infarction: 5
year follow-up of a trial conducted by the Interuniversity Cardiol- 
ogy Institute of the Netherlands. J Am Coil Cardio11989;14:1609- 
15. 
8. Cerqueira MD, Maynard C, Ritchie JL, Davis KB, Kennedy JW. 
Long-term survival in 618 patients from the Western Washington 
streptokinase in myocardial infarction trials. J Am Col1 Cardiol 
1992;20:1452-9. 
9. Baigent C, Collins R, Appleby R, et al., for the ISIS collaborative 
group. ISIS-2 10 year survival among patients with suspected acute 
myocardial infarction in randomized comparison of intravenous strep- 
tokinase, oral aspirin, both or neither. BMJ 1998;316:1337-43. 
10. Franzosi MG, Santoro E, De Vita C, et al. Ten-year follow-up of the 
first megatfial testing thrombolytic therapy in patients with acute 
myocardial infarction. Results of the Gruppo Italiano per lo Studio 
della sopravvivenza nelrInfarto-1 study. Circulation 1998;98:2659-65. 
11. The GUSTO Investigators. An international randomized trial com- 
paring four thrombolytic strategies for acute myocardial infarction. 
N Engl J Med 1993;329:673-82. 
12. K1eiman NS, White HD, Ohman M, et al. Mortality within 24 hours 
of thrombolysis for myocardial infarction: the importance of early 
reperfusion. Circulation 1994;90:2658-65. 
13. Nunn CM, O'Neill WW, Rothbaum D, et al. Long-term outcome 
after primary angioplasty: report from the primary angioplasty 
myocardial infarction (PAMI-I) trial J Am Coil Cardiol 1999;33: 
640- 6. 
14. Gibson M, Giugliano RP, Anderson K, et al. Abciximab enhances 
thrombolysis: a comparison of abciximab alone versus abciximab plus 
low dose thrombolytics using the corrected TIMI frame count (abstr). 
Circulation 1998;I-559. 
